Research map: Circulating tumour DNA and molecular residual disease in oesophageal cancer: Clinical readiness, evidence gaps and trial-ready applications

Back to the article

Papers in this map

  1. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial · Salah‐Eddin Al‐Batran · 2019 · 2702 citations · Cited by this paper
  2. TROP-2 in solid tumors: From oncogenic driver to therapeutic target with antibody-drug conjugates · 2026 · Related
  3. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer · Ronan Joseph Kelly · 2021 · 1874 citations · Cited by this paper
  4. Molecular mechanisms of targeted therapy in breast cancer: An integrated signaling network perspective · 2026 · Related
  5. The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020 · Eileen Morgan · 2022 · 1223 citations · Cited by this paper
  6. The adipose microenvironment in colorectal cancer: Navigating the nexus of inflammation, metabolism, and metastatic reprogramming · 2026 · Related
  7. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer · Jeanne Tie · 2022 · 1082 citations · Cited by this paper
  8. Biomimetic nanoparticles for metastatic breast cancer: Advancing targeted drug delivery beyond conventional nanomedicine · 2026 · Related
  9. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group · Javier Pascual · 2022 · 738 citations · Cited by this paper
  10. Remodeling the immune microenvironment: Engineering IL-2 variants to overcome clinical bottlenecks in PD-1 inhibitor plus chemotherapy · 2026 · Related
  11. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up · Radka Lordick Obermannova · 2022 · 738 citations · Cited by this paper
  12. Extracellular vesicle-mediated immunity-coagulation interaction in cancer-associated thrombosis during the immunotherapy era · 2026 · Related
  13. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology · Jaffer A. Ajani · 2023 · 576 citations · Cited by this paper
  14. Revisiting Diffuse Gliomas in the Era of Precision Medicine: Molecular Insights and Therapeutic Implications · 2026 · Related
  15. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer · Isaac García-Murillas · 2019 · 438 citations · Cited by this paper
  16. Liquid biopsy for early cancer detection in hereditary cancer syndromes: Current evidence · 2026 · Related
  17. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA · Christopher Abbosh · 2023 · 388 citations · Cited by this paper
  18. Current status and prospects of chemotherapy-free strategies in ovarian cancer · 2026 · Related
  19. Oesophageal cancer · Hong Yang · 2024 · 296 citations · Cited by this paper
  20. Advances in the mechanisms of exosome-derived non-coding RNAs regulating T-cell infiltration in tumors · 2026 · Related
  21. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer · Tej Deepak Azad · 2019 · 286 citations · Cited by this paper
  22. Minimal residual disease as a target for liquid biopsy in patients with solid tumours · Klaus Pantel · 2024 · 130 citations · Cited by this paper
  23. Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, and large-sample informatics study · Song‐Bin Guo · 2024 · 126 citations · Cited by this paper
  24. Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery · Arianna Barbetta · 2018 · 84 citations · Cited by this paper
  25. Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers · Brandon M. Huffman · 2022 · 78 citations · Cited by this paper
  26. Noninvasive diagnosis and monitoring of mutations by deep sequencing of circulating tumor DNA in esophageal squamous cell carcinoma · Honglei Luo · 2016 · 51 citations · Cited by this paper
  27. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma · Hoi Yan Ng · 2023 · 46 citations · Cited by this paper
  28. Immune-related adverse events of neoadjuvant immunotherapy in patients with perioperative cancer: a machine-learning-driven, decade-long informatics investigation · Song‐Bin Guo · 2025 · 41 citations · Cited by this paper
  29. Clinical utility and applicability of circulating tumor DNA testing in esophageal cancer: a systematic review and meta-analysis · Swathikan Chidambaram · 2021 · 38 citations · Cited by this paper
  30. Minimal residual disease profiling predicts pathological complete response in esophageal squamous cell carcinoma · Pinli Yue · 2024 · 22 citations · Cited by this paper
  31. Association between plasma circulating tumor DNA and the prognosis of esophageal cancer patients: a meta-analysis · Haowen Zhang · 2024 · 18 citations · Cited by this paper
  32. Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring · Heng Jiao · 2025 · 16 citations · Cited by this paper
  33. Pretreatment Primary Tumor Stage is a Risk Factor for Recurrence in Patients with Esophageal Squamous Cell Carcinoma Who Achieve Pathological Complete Response After Neoadjuvant Chemoradiotherapy · Roberta La Mendola · 2020 · 15 citations · Cited by this paper
  34. Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction · Xinxing Li · 2024 · 15 citations · Cited by this paper
  35. Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response · Eric Michael Lander · 2024 · 15 citations · Cited by this paper
  36. Circulating tumor DNA as a biomarker for progression and survival in esophageal cancer after neoadjuvant therapy and esophagectomy: a systematic review and meta-analysis · Tianzheng Shen · 2025 · 13 citations · Cited by this paper
  37. Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study · Hesong Wang · 2024 · 11 citations · Cited by this paper
  38. Circulating tumor DNA monitoring detects minimal residual disease and predicts outcomes in patients with esophageal adenocarcinoma or squamous cell carcinoma after esophagectomy · Qingjiang Hu · 2025 · 7 citations · Cited by this paper
  39. Exploring the Clinical Value of Perioperative ctDNA ‐Based Detection of Molecular Residual Disease in Patients With Esophageal Squamous Cell Carcinoma · Jimin Li · 2025 · 5 citations · Cited by this paper

Source: OpenAlex (CC0)